Get set for a suckers' rally. On Monday, Guilin Sanjin Pharmaceutical, China's biggest producer of herbal lozenges, should rustle up the nation's first initial public offering since September. The resumption of festivities is long overdue. But more important is the regulatory overhaul that accompanies it. The stated aim is to shift closer to international norms, where institutional demand rather than the regulator sets stock prices.
等着迎接一轮“傻瓜涨势”吧。周一，manbetx3.0 最大草药润喉片生产商桂林三金药业(Guilin Sanjin Pharmaceutical)将启动去年9月以来该国第一宗首次公开发行(IPO)。这样的“喜庆日子”早就应该恢复。但更重要的是随之而来的监管改革。其公开目标是要向国际惯例靠拢，由机构需求（而非监管者）决定股票价格。
您已阅读24%（593字），剩余76%（1927字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。